Regeneron Pharmaceuticals, Inc.
807.65USD
-2.6600 (-0.33%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $16▲ | $13.08 | 20 | 0 |
| Next quarter | $15.61▲ | $13.06 | 19 | 1 |
| Current year | $53.55▲ | $46.25 | 23 | 0 |
| Next year | $50.38▲ | $48.1 | 5 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $10.21 | $14.29 | +4.08 (+40.0%) |
| 2026-03-31 | $8.9 | $9.47 | +0.57 (+6.4%) |
| 2025-12-31 | $10.75 | $11.44 | +0.69 (+6.4%) |
| 2025-09-30 | $9.64 | $11.83 | +2.19 (+22.7%) |
545 ratings from 45 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Market Perform | $641 $824 | Aug 17, 2026 |
| Citigroup | Maintained | Neutral | $700 $740 | Aug 3, 2026 |
| Guggenheim | Maintained | Buy | $1,000 $1,030 | Aug 3, 2026 |
| RBC Capital | Maintained | Sector Perform | $696 $737 | Jul 31, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $730 $758 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $750 $795 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $700 $750 | Jul 31, 2026 |
| Truist Securities | Maintained | Buy | $769 $772 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $995 $1,000 | Jul 21, 2026 |
| Piper Sandler | Maintained | Overweight | $855 $854 | Jul 9, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $788 $730 | Jul 8, 2026 |
| RBC Capital | Maintained | Sector Perform | $707 $696 | Jul 7, 2026 |
| Truist Securities | Maintained | Buy | $778 $769 | Jul 7, 2026 |
| Benchmark | Upgraded from Hold | Buy | $185 | Jul 7, 2026 |
| HSBC | Maintained | Buy | $990 $880 | Jul 6, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $785 $750 | Jul 6, 2026 |
| Canaccord Genuity | Maintained | Buy | $1,057 $875 | May 19, 2026 |
| BMO Capital | Maintained | Outperform | $900 $730 | May 18, 2026 |
| Truist Securities | Maintained | Buy | $796 $778 | May 18, 2026 |
| JP Morgan | Maintained | Overweight | $950 $850 | May 18, 2026 |
| Piper Sandler | Maintained | Overweight | $875 $855 | May 18, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $800 $700 | May 18, 2026 |
| RBC Capital | Maintained | Sector Perform | $762 $707 | May 18, 2026 |
| Citigroup | Downgraded from Buy | Neutral | $900 $700 | May 18, 2026 |
| Leerink Partners | Downgraded from Outperform | Market Perform | $792 $641 | May 18, 2026 |
81 filings from 21 insiders · 5 buy / 7 sell over 6m
Officers and directors of REGN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McCourt MarionOfficer, EVP Commercial | Sell | 1.1k | $857.39 | $970k | Sep 3, 2026 |
| Guarini KathrynDirector | ExerciseNon-Qualified Stock Option (right to buy) | 400 | — | — | Sep 2, 2026 |
| Guarini KathrynDirector | Sell | 400 | $850.00 | $340k | Sep 2, 2026 |
| Guarini KathrynDirector | Exercise | 400 | $719.37 | $288k | Sep 2, 2026 |
| McCourt MarionOfficer, EVP Commercial | Sell | 1.2k | $850.00 | $1.03M | Sep 2, 2026 |
| LAROSA JOSEPH JGeneral Counsel | Exercise | 12.3k | $381.92 | $4.69M | Aug 19, 2026 |
| FENIMORE CHRISTOPHER RChief Financial Officer | Exercise | 6.3k | $381.92 | $2.40M | Aug 18, 2026 |
| GUARINI KATHRYN PH.D.Director | Sell | 400 | $800.00 | $320k | Aug 10, 2026 |
| ZOGHBI HUDA YDirector | Sell | 800 | $800.00 | $640k | Aug 10, 2026 |
| GUARINI KATHRYN PH.D.Director | Exercise | 400 | $719.37 | $288k | Aug 10, 2026 |
| ZOGHBI HUDA YDirector | Exercise | 800 | $376.69 | $301k | Aug 10, 2026 |
| RYAN ARTHUR F.Director | Sell | 200 | $650.15 | $130k | Jul 2, 2026 |
| RYAN ARTHUR F.Director | Sell | 100 | $701.76 | $71k | May 1, 2026 |
| RYAN ARTHUR F.Director | Sell | 100 | $771.32 | $78k | Apr 1, 2026 |
| RYAN ARTHUR F.Director | Sell | 100 | $777.46 | $79k | Mar 2, 2026 |
| ZOGHBI HUDA YDirector | Sell | 1.6k | $774.68 | $1.28M | Feb 19, 2026 |
| ZOGHBI HUDA YDirector | Exercise | 1.6k | $376.69 | $617k | Feb 19, 2026 |
| RYAN ARTHUR F.Director | Sell | 100 | $775.63 | $78k | Feb 9, 2026 |
| PITOFSKY JASONOfficer | Sell | 2.0k | $775.95 | $1.59M | Feb 9, 2026 |
| PITOFSKY JASONOfficer | Exercise | 1.0k | $492.00 | $492k | Feb 9, 2026 |
No analyst notes on REGN yet.
Analyst Ratings
27 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 14 | 9 | 0 | 1 | Buy2.29 |
| 1 mo ago | 4 | 14 | 9 | 0 | 1 | Buy2.29 |
| 2 mo ago | 4 | 14 | 10 | 0 | 0 | Buy2.21 |
| 3 mo ago | 5 | 16 | 8 | 0 | 0 | Buy2.10 |